Search Results for: CLINICAL TRIALS Accelerating the Clinical
Articles
NANOPARTICLES - A Revolution in the Development of Drug Delivery Vehicles June 1, 2017
Tim Leaver explains how his company has developed a proprietary technology for the rapid development of nanoparticles and seamless scale-up for clinical studies and commercial production, and how it is transforming the development and manufacturing of a range of nanoparticle formulations from a hit-and-miss affair to a standardized process, accelerating novel nanomedicines from the bench to the clinic.
Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems May 31, 2017
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company...Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems May 31, 2017
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company...Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems May 31, 2017
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company...Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems May 31, 2017
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company...Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems May 31, 2017
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company...Incyte & Calithera Biosciences Announce Global Collaboration February 7, 2017
Incyte Corporation and Calithera Biosciences, Inc. recently announced the companies have entered into a global collaboration and license agreement for...Boost Vaccination Data Encourage Continued Development of Parkinson's Vaccine September 12, 2016
AFFiRiS AG recently announced results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE PD01A, an...EXECUTIVE INTERVIEW - DelMar Pharmaceuticals: Polishing NCI Diamonds in the Rough With Modern Science June 30, 2016
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have...RIGHTS MANAGEMENT PROTECTION - You Have the Right to Remain Protected June 1, 2016
Tom Johnson says on the surface, rights management protection may look like another expense and another system to maintain, and while that may be true, it is a critical security component that delivers rapid and significant return on investment.
ICON Selected by Genomics England to Support Largest Genome Sequencing Project February 16, 2016
ICON plc recently announced it has been selected by Genomics England as data management partner for the 100,000 Genomes Project....PlasmaTech Announces Name Change to Abeona Therapeutics; Reflects Broader Rare Disease Commitment June 19, 2015
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe...Emulate Announces Strategic Collaboration With Johnson & Johnson Innovation to Use Organs-on-Chips Platform June 18, 2015
Emulate, Inc. recently announced that it recently formed a research collaboration with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of...SPECIAL FEATURE - Outsourcing Formulation & Manufacturing Development: Using Data & Unique Approaches to Solve Solubility Issues, Target Profiles & Customize Products March 31, 2015
Contributor Cindy H. Dubin finds that CMOs are embracing development projects in an effort to establish longer-lasting partnerships with their pharma and biotech clients. These contract developers are deploying innovative techniques aimed at improving solubility and fast-tracking products to market.
MARKET BRIEF - Miniaturizing Healthcare - From Microelectronics to Nanobiosensing March 3, 2015
Cecilia Van Cauwenberghe, MS, Technical Insights Senior Research Analyst, Frost & Sullivan, reports that the proliferation of lower cost microfluidics-based genomics tools offering improved capabilities and allowing more access to end-users is expected to drive this technology for pharmaceutical and biomedical research throughout the next 5 years.
SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
BIOAVAILABILITY ENHANCEMENT - Potential for Expanding Chemical Space September 2, 2014
Marshall Crew, PhD, focuses on considering what might be achieved if we borrow best practices and processes that have assisted other industries facing growing complexity, in fact, much of the advances in accelerating our solubilization processes are already borrowed from other industries, in many cases even the technologies.
EXECUTIVE INTERVIEW - The Integration of Bend Research With Capsugel Dosage Form Solutions (DFS) June 4, 2014
Drug Development Executive: Rod Ray, former Bend Research CEO and now a member of Capsugel’s Scientific and Business Advisory Board, talks about the enhanced capabilities of Capsugel DFS and the advantages offered to companies developing new and/or enhanced medicines.
MARKET BRIEF - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs November 18, 2013
Adam M. Dion, MS, summarizes GlobalData’s recent CRO Benchmark Report and believes the dynamics of pharmaceutical outsourcing and location decisions in emerging markets are changing. Cost reduction is being augmented and will gradually be eclipsed by footprint growth as a major factor shaping decisions, and CROs are realizing that the ability to be on the ground closer to their customers is a key building block to establishing sustainable, long-term relationships with clients.
EXECUTIVE INTERVIEW - Capsugel DFS: Integrating Technology for Innovative Finished Dosage Forms October 2, 2013
Drug Development Executive: Amit Patel, President of Capsugel’s Dosage Form Solutions business unit, speaks about the formulation challenges facing the industry and the increasing pressure on companies to remain competitive in today’s dynamic marketplace.
WHITEPAPER: Lonza Engine® & Xcelodose®: Accelerating Preclinical & Clinical Trial Pathways With Target Dosing Technologies
Learn how Lonza helps developers quickly assess new drug candidates while minimizing API consumption through efficient excipient screenings, encapsulation and...
